REGORAFENIB, TRIFLURIDINE, COMBINATIONS, SACITUZUMAB GOVITECAN , BEVACIZUMAB clinical trials

A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory colorectal cancer patients (TROPHIT1)

This study is looking at a new treatment called sacituzumab govitecan for bowel cancer that has spread and isn't responding to other treatments. It compares this new drug to standard treatments to see which works best at stopping the cancer from growing.